Pharmaceutical

Boehringer and Cue Biopharma to develop autoimmune therapies

Boehringer and Cue Biopharma have entered a strategic research partnership and licence agreement for the latter’s CUE-501.

Apr 16, 2025 - 06:00
Boehringer and Cue Biopharma to develop autoimmune therapies
Boehringer and Cue Biopharma have entered a strategic research partnership and licence agreement for the latter’s CUE-501.
Read the original article

Tags:

Previous Article

The 7MM atopic dermatitis market to experience growth, reaching $22.4bn by 2033

Next Article

J&J projects $400m tariff hit but raises sales outlook

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Pfizer boasts over 30% increase in Q3 revenues against previous year

Pfizer boasts over 30% increase in Q3 revenues against ...

Nov 1, 2024

Patient advocates warn FDA proposal on salt intake could do fatal harm to people with kidney disease

Patient advocates warn FDA proposal on salt intake coul...

Aug 15, 2023

BGB-30813 by BeiGene for Head And Neck Squamous Cell Ca...

Dec 26, 2023